Neovacs
Records under this name other than the patents Neovacs holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,993,565 | Method for treating IFNalpha related conditions Lapsed on the fee record Ended Jun 12, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 12, 2026 | From the USPTO record |
| US 8,372,388 | Method for preparing a stable TNF-α vaccine Term ended Term ended Dec 6, 2024 · From the USPTO record | Term ended | Term ended Dec 6, 2024 | From the USPTO record |
| US 7,972,603 | Stable immunogenic product comprising antigenic heterocomplexes Term ended Term ended Sep 16, 2023 · From the USPTO record | Term ended | Term ended Sep 16, 2023 | From the USPTO record |
| US 8,697,047 | Stable immunogenic product comprising antigenic heterocomplexes Term ended Term ended Sep 16, 2023 · From the USPTO record | Term ended | Term ended Sep 16, 2023 | From the USPTO record |
| US 7,015,016 | Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA's Term ended Term ended Feb 9, 2022 · From the USPTO record | Term ended | Term ended Feb 9, 2022 | From the USPTO record |
| US 6,420,141 | Anti-HIV immunogens (toxoids), preparation methods and use for preventing and treating aids Formerly held Term ended Term ended Mar 15, 2021 · From the USPTO record | Term ended | Term ended Mar 15, 2021 | From the USPTO record |
| US 6,200,575 | Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them Term ended Term ended May 15, 2020 · From the USPTO record | Term ended | Term ended May 15, 2020 | From the USPTO record |
| US 6,878,370 | Chemically modified TNF-α Term ended Term ended Apr 20, 2020 · From the USPTO record | Term ended | Term ended Apr 20, 2020 | From the USPTO record |
| US 7,351,554 | Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's Lapsed on the fee record Ended Apr 1, 2020 · From the USPTO record | Lapsed on the fee record | Ended Apr 1, 2020 | From the USPTO record |
| US 8,101,165 | Use of immunogens to treat or prevent, in malignant tumors, the immune or vascular disorders induced by extracellular factors Lapsed on the fee record Ended Jan 24, 2020 · From the USPTO record | Lapsed on the fee record | Ended Jan 24, 2020 | From the USPTO record |